ANT308
ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the studies of acute myeloid leukemia (AML) and uveal melanoma (UVM).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2871680-36-1
- Formule: C156H261N47O40S
- Masse moléculaire:3467.10
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform PACAP Receptor
More
Activité biologique
Description
In Vitro
ANT308 (1-10 μM, 48 h) significantly enhances CD69 and Ki67 expressions in CD4+ and CD8+ T cells[1].
ANT308 (0.1-10 μM, 72 h) reduces the viability of B16F10 and HT-144 cells dose-dependently[2].
ANT308 (10 μM, 72 h) decreases the proportion of cells in S phase, and induces apoptosis in B16LS9 and Mel 290 cells[2].
ANT308 (10 μM, 8 h) significantly inhibits cell migration in the B16LS9, Mel290, and HT-144 cell lines[2].
ANT308 (72 h) reduces MCAM and N-cadherin expression by inhibiting VIP-VPAC2 signaling[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:B16F10 and HT-144 cells
-
Concentration:0.1, 1, 5 and 10 μM
-
Incubation Time:72 h
-
Result:Decreased the numbers of viable B16F10 and HT-144 cells by around 46% and 27%, respectively, compared to control cultures with 5 μM twice daily.
-
Cell Line:B16LS9 and Mel 290 cells
-
Concentration:10 μM
-
Incubation Time:72 h
-
Result:Increased percentages of apoptotic cells.
-
Cell Line:B16LS9 and Mel 290 cells
-
Concentration:10 μM
-
Incubation Time:72 h
-
Result:Decreased cells in the S phase.
-
Cell Line:B16LS9, B16F10, Mel 290 cells, HT-144 cells
-
Concentration:10 μM
-
Incubation Time:8 h
-
Result:Significantly inhibited cell migration in the B16LS9, Mel290, and HT-144 cell lines
In Vivo
ANT308 (100 μg/100 μL PBS, s.c., twice a day for 10 days) reduces the number and size of liver metastases of mice following intraocular or subcutaneous melanoma injection, and shows a trend toward reducing tumor volume at the primary tumor site[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:P815 cells induced AML model established in DBA/2j (H2Kd) mice[1]
-
Dosage:6 nmol
-
Administration:Subcutaneous injection (s.c.), once daily for 10-14 weeks
-
Result:Significantly prolonged the survival period of mice and reduced the tumor burden.
-
Animal Model:B16LS9 induced UVM model and B16LS9 or B16LS9 induced subcutaneous melanoma model established in female C57BL6/J mice (8-10 weeks) and NRG (NOD Rag gamma) mice (10-11 months old)[2]
-
Dosage:100 μg/100 μL PBS
-
Administration:Subcutaneous injection (s.c.), twice a day for 10 days
-
Result:Significantly reduced the number of liver metastases. Reduced MCAM, but had no significant effect on N-cadherin expression. had no significant effect on subcutaneous tumor volume.
Chemical Information
-
CAS No. 2871680-36-1
-
Masse moléculaire 3467.10
-
Formule C156H261N47O40S
-
SMILES
O=C(N1[C@@H](CCC1)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N2[C@@H](CCC2)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CC4=CC=C(C=C4)O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCSC)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC5=CC=C(C=C5)O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCCN)N
-
Sequence
Lys-Pro-Arg-Arg-Pro-Tyr-Thr-Ser-Asp-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Leu-Ile-Leu-Asn
-
Sequence Shortening
KPRRPYTSDYTRLRKQMAVKKYLNLILN
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)